Pancreatic Cancer Research

ResearcherUniversity of TübingenActive in the last 2 years

Przemyslaw M. Bozko

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8126-3686; OpenAlex author ID A5027965195. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 3

  1. High p53 Protein Level Is a Negative Prognostic Marker for Pancreatic Adenocarcinoma. Last author DOI 10.3390/ijms252212307↗
  2. Therapeutic effects of Argyrin F in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.003↗
  3. Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. First author DOI 10.1093/carcin/bgt394↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sebastian M. Klein · 1 shared paper, 2024 · strength 0.28
  2. Ruben R. Plentz · 2 shared papers, 2014–2017 · strength 0.11
  3. Bence Sipos · 2 shared papers, 2014–2017 · strength 0.11
  4. Xi Chen · 1 shared paper, 2017 · strength 0.07
  5. Vindhya Palagani · 1 shared paper, 2014 · strength 0.04
  6. Nathalia A. Giese · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.